Dr. Sagar Lonial and Dr. Xavier Leleu discuss updates in smoldering myeloma, the treatment of both transplant-eligible and transplant-ineligible patients, the treatment of relapse/refractory patients, and new agents.
We just added a series of videos with two of the world leading experts in the treatment of myeloma. Dr. Xavier Leleu from the Centre Hospitalier Universitaire de Lille and Dr. Sagar Lonial from Emory University School of Medicine discuss the highlights of new myeloma...read more
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...read more
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...read more
Featured Multiple Myeloma News
The U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four...read more
In the phase III OPTIMISMM trial, reported by Richardson et al in The Lancet Oncology, researchers found that the addition of pomalidomide to bortezomib/dexamethasone improved progression-free survival in relapsed or refractory multiple myeloma previously treated...read more
Poseida Therapeutics Receives FDA Orphan Drug Designation For P-BCMA-101 For The Treatment Of Multiple Myeloma
SAN DIEGO, May 13, 2019 — Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced the United States Food and Drug Administration...read more
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
Designation could accelerate CLR 131 development and underscores the need for new treatments FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development...read more
The U.S. Centers for Medicare and Medicaid Services will slightly increase coverage for expensive CAR-T cell therapies. CMS, which runs the federal government’s healthcare plan for seniors, issued a proposed rule raising its maximum “new technology add-on payment”...read more
Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma
Company Announcement: Source -- Phase III study to examine daratumumab plus lenalidomide as maintenance treatment in patients with newly diagnosed multiple myeloma -- Study utilizes the subcutaneous formulation of daratumumab -- Study expected to start in the first...read more
Ask the Experts
A new video from our partners at OncLive discusses how Dr. Fakhri selects treatment regimens for her patients. Currently, physicians use 2 factors to pick a regimen for a patient—transplant eligibility versus ineligibility and the genomics of their disease,...read more
Watch this video CME from our partners at Plexus Communications on the management of patients with multiple myeloma. Ola Landgren, MD, PhD, co-chair of the World Myeloma Forum, discusses the diagnosis, staging, risk stratification, cytogenetics, and treatment...read more
Dr. Yasar Shad, a Hematology/Oncology fellow from Columbia MO, asked where he might find additional reading/references on the cytogenetics and molecular genetics of multiple myeloma. We just wrote this very recent update. It includes current and future technologies. I...read more
Join Our Community
By joining the Myeloma360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.